Also, combination therapies may enhance tumor cell immunogenicity while reducing the efficacy of immunosuppressive molecules such as indoleamine 2,3-dioxygenase (IDO), C-X-C Motif chemokine receptor 2 (CXCR2), lymphocyte-activation gene 3 (LAG-3), phosphoinositide 3-kinase (P13K), for example [48, 50]. The gene discussed is IDO2; the disease is neoplasm.